Małgorzata M.
- Country
- Poland
- Department
- Oncology Clinic
Research Overview
- CAMBRIA-1: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Extended Therapy With Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in Patients with ER+/HER2- Early Breast Cancer and an Intermediate or High Risk of Recurrence Who Have Completed Definitive Locoregional Therapy and at Least 2 Years of Standard Adjuvant Endocrine-Based Therapy Without Disease Recurrence
- CAMBRIA-2: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-High or High Risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease
Data & Insights
Has run more than one trial at 115 of 319 partner sites.
Specializations
Breast Cancer Therapeutics
The investigator specializes in treating hormone receptor-positive (ER+) and HER2-negative breast cancer, with particular focus on early-stage disease management. Their research encompasses extended endocrine therapy approaches for breast cancer treatment.
- Early-stage breast cancer treatment
- Hormone receptor-positive disease management
- Extended adjuvant therapy
Their therapeutic interests include innovative approaches in endocrine-based treatments and novel therapeutic agents for breast cancer care.
Endocrine Therapy Innovation
The investigator focuses on advancing adjuvant endocrine therapy strategies, particularly in the context of extended treatment duration. Their work explores new therapeutic options beyond standard endocrine treatments.
- Novel endocrine agents
- Extended therapy protocols
- Treatment optimization strategies
Their research interests include investigating therapeutic superiority of novel agents compared to standard endocrine treatments.
Cancer Recurrence Prevention
The investigator specializes in developing strategies for breast cancer recurrence prevention, with emphasis on extended therapeutic approaches. Their work focuses on improving long-term outcomes in early breast cancer.
- Recurrence risk reduction
- Long-term treatment strategies
- Clinical outcome improvement
Their expertise includes evaluation of extended adjuvant therapy benefits in preventing disease recurrence.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.